SOPH
SOPHiA GENETICS S.A.NASDAQHealthcare$5.04-1.79%ClosedMarket Cap: $361.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
7.17
P/S
4.59
EV/EBITDA
-5.30
DCF Value
$-25.24
FCF Yield
-11.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.4%
Operating Margin
-91.2%
Net Margin
-102.2%
ROE
-117.0%
ROA
-48.3%
ROIC
-61.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $21.7M | 67.7% | $-18.0M | $-19.2M | $-0.28 | — |
| FY 2025 | $77.3M | 61.9% | $-70.9M | $-79.0M | $-1.17 | — |
| Q3 2025 | $19.5M | 66.3% | $-17.9M | $-20.0M | $-0.30 | — |
| Q2 2025 | $18.3M | 67.0% | $-18.6M | $-22.4M | $-0.33 | — |
| Q1 2025 | $17.8M | 68.7% | $-16.0M | $-17.4M | $-0.26 | — |
| Q4 2024 | $17.7M | 68.2% | $-17.4M | $-15.2M | $-0.23 | — |
| FY 2024 | $65.2M | 67.4% | $-66.6M | $-62.5M | $-0.95 | — |
| Q3 2024 | $15.9M | 67.2% | $-15.4M | $-18.4M | $-0.28 | — |
| Q2 2024 | $15.8M | 68.2% | $-15.0M | $-15.2M | $-0.23 | — |
| Q1 2024 | $15.8M | 65.9% | $-18.8M | $-13.7M | $-0.21 | — |
| Q4 2023 | $17.0M | 69.8% | $-18.9M | $-24.1M | $-0.37 | — |
| FY 2023 | $62.4M | 68.8% | $-74.8M | $-79.0M | $-1.22 | — |